LGALS3 and idiopathic pulmonary fibrosis: These data indicate a potential opportunity to exploit Gal-3 as a therapeutic target in ALI and support the progression of GB0139 into the Phase IIb GALACTIC-1 study (NCT03832946) in patients with IPF.